Pittsburgh-based Mylan Inc. Nov. 28 announced that the Food and Drug Administration has approved its generic version of Pharmacia & Upjohn’s Zinecard (dexrazoxane for injection) packaged in 250 mg and 500 mg single-use vials.
Zinecard for injection is indicated for the prevention of cardiomyopathy associated with the administration of the cancer drug doxorubicin, according to FDA’s website.
Dexrazoxane for injection, for the Zinecard indication, had U.S. sales of approximately $3.4 million for the 12 months ending Sept. 30, according to IMS Health.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.